AlWaheidi Shaymaa, McPherson Klim, Chalmers Iain, Sullivan Richard, Davies Elizabeth A
Cancer Epidemiology, Population and Global Health, King's College London, London, United Kingdom.
Public Health Epidemiology, Nuffield Department of Primary Health Care Research and New College, University of Oxford, Oxford, United Kingdom.
JCO Glob Oncol. 2020 Nov;6:1772-1790. doi: 10.1200/JGO.19.00383.
To critically review the evidence and opinions expressed about mammographic screening (MS) in research reports on breast cancer in the occupied Palestinian territory (oPt) and to assess whether benefits and harms in MS are presented in a balanced way.
Searches of PubMed, Cochrane, MEDLINE, EMBASE, CINAHL, and gray literature identified 14 eligible research reports relating to the oPt. We reviewed these documents and then used a thematic analysis to describe and analyze the evidence and the opinions about MS expressed in them.
All 14 research reports mentioned that MS would improve survival rates in the oPt. Only three gave information on major harmful effects, and only two emphasized that MS must be accompanied by effective treatment to have any beneficial effects on population mortality. There was no consistency in the recommended frequency of MS.
Most information presented by Palestinian health researchers was selective and failed to address the important established harms of MS. Thus, calls to support MS in the oPt are not based on a measured discussion of the risks and benefits for women or grounded in the systemic readiness of health care necessary for its effectiveness. As long as diagnostic and treatment facilities remain deficient, screening cannot lead to reduced mortality from breast cancer.
批判性地审视关于巴勒斯坦被占领土(oPt)乳腺癌研究报告中有关乳腺钼靶筛查(MS)的证据和观点,并评估MS的益处和危害是否得到了平衡呈现。
检索PubMed、Cochrane、MEDLINE、EMBASE、CINAHL以及灰色文献,确定了14篇与oPt相关的符合条件的研究报告。我们对这些文献进行了综述,然后采用主题分析来描述和分析其中关于MS的证据和观点。
所有14篇研究报告均提到MS将提高oPt的生存率。只有3篇报告提供了主要有害影响的信息,只有2篇强调MS必须伴有有效治疗才能对人群死亡率产生有益影响。MS的推荐筛查频率并不一致。
巴勒斯坦卫生研究人员提供的大多数信息具有选择性,未能提及MS已明确的重要危害。因此,在oPt支持MS的呼吁并非基于对女性风险和益处的审慎讨论,也并非基于其有效实施所需的医疗系统准备情况。只要诊断和治疗设施仍然不足,筛查就无法降低乳腺癌死亡率。